Every earnings call for STYRENIX — management tone, guidance, KPIs and promise tracking, quarter by quarter.
STYRENIX · 6 transcripts · Chemicals · latest Q4 FY26EBITDA (Consolidated) ₹128 cr; EBITDA Margin (Consolidated) 15.3%; PAT (Consolidated) ₹74 cr. Q4 FY26 Standalone EBITDA grew 51.9% to INR 126 crores.
Read full transcript & analysisStandalone EBITDA ₹76 cr (+0% YoY); Standalone EBITDA Margin 11.7%; Standalone PAT ₹44 cr (−7% YoY). Standalone EBITDA margins improved by 800 bps to 11.7% in Q3 FY26.
Read full transcript & analysisStandalone Revenue ₹615 cr (−6% YoY). Standalone Q2 FY26 Revenue declined 5.8% YoY to ₹615 crores.
Read full transcript & analysisConsolidated Revenue ₹944 cr; Consolidated PAT ₹52 cr. Standalone Sales Volume: 51.8 KT, up 8.1% QoQ, highest ever sales.
Read full transcript & analysisConsolidated Revenue (FY25) ₹2,982 cr; Consolidated PAT (FY25) ₹235 cr; Consolidated PAT Margin (Q4 FY25) 6%. Consolidated Revenue for FY25 stood at ₹2,982 crores, with a sales volume of 203 KT.
Read full transcript & analysisRevenue ₹691 cr (+42% YoY); PAT ₹48 cr; PAT Margin 6.3%. Q3 FY25 Sales volume increased by 34.4% YoY to 47.5 KT.
Read full transcript & analysis